Highlights
IIA supported (ever)1 patent
About
Novel Drugs for Neurodegenerative Diseases
Neuromagen Pharma is a pharmaceutical company developing a new class of innovative small molecules that activate telomerase reverse transcriptase (TERT), an enzyme that plays a major role in preventing cellular senescence.
The companys mission is to develop drugs to delay the onset and the progression of neurodegenerative diseases such as ALS and to improve and extend patients lives.
Neuromagen Pharma received FDA Orphan Drug Designation for its AGS-499 Drug Candidate to Slow the Progression of ALS (Amyotrophic Lateral Sclerosis).
Identity
| Name | Neuromagen Pharma |
|---|---|
| Slug | neuromagen |
| Type / kind | startup |
| Crunchbase ID | neuromagen-pharma |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4M_bk9UKDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | South District |
| HQ city | Be'er Sheva |
| HQ address | HaEnergia Street 77, Be'er Sheva, Israel |
Web & social
| Website | https://www.neuromagen.com/ |
|---|---|
| https://www.linkedin.com/company/80297359 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCellsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
pharmaceuticalsamyotrophic-lateral-sclerosis-alsdegenerative-diseasesdrug-developmentcells
Funding
| Total raised | $2.5M |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}